Notably, preclinical and clinical data indicate that compared with other mTOR inhibitors, novel dual-space mTOR inhibitors can significantly promote cancer regression by inhibiting 4E-BP1 phosphorylation and reducing adaptive resistance by alleviating feedback inhibition of receptor tyrosine kinase (RTK) expression. Here, NTRK1 is linked to cancer.